HCV Treatment:  The current treatment for hepatitis C, including outcomes, side effects and treatment of various HCV populations

 

·        Acute Infection

o       1233. Rapid virologic response is common in acute hepatitis C virus (HCV) infection regardless of genotype. 

 

·        Drug Resistance

o       266. Naturally occurring STAT-C resistance mutations in treatment-naïve HCV infected patients - an international multi-center study.

 

·        General

o       168. A Randomized, Double-Blind, Placebo-Controlled Study of PPAR-gamma Agonist Pioglitazone Given in Combination with Peginterferon and Ribavirin in Patients with Genotype-1 Chronic Hepatitis C.

o       263. Sustained Virological Response is Associated with Decrease in Liver Stiffness Using FibroScan in Patients with HCV Related Cirrhosis.  

o       264. Lower Risk of Hepatocellular Carcinoma and Improved Survival in patients with HCV Related Cirrhosis with Sustained Virological Response.

o       267. Decline in Sexual Desire, Function and Satisfaction in Men During Peginterferon and Ribavirin Therapy for Chronic Hepatitis C.

o       520. Sustained virological response (SVR) to pegylated interferon and ribavirin has no effect on neurocognition and cerebral metabolite levels in patients with chronic hepatitis C.

o       521. Hepatitis c among HEAVY ALCOHOL CONSUMERS : Does it require treatment?

o       1220. Anti-viral therapy in haemodialyzed HCV patients: efficacy, tolerance and treatment strategy.

o       1232. Re-infection following successful treatment for Hepatitis C virus Infection. (updated Nov 3, 2008)

o       1241. Interferon therapy for hepatitis C patients curatively treated for hepatocellular carcinoma with percutaneous therapies.  (updated Nov 3, 2008)

o       1242. Sustained Virological Response in Patients with Chronic Hepatitis C is Similar Between Whites and Non-Whites: Evaluation Using Specific Ancestry Alleles Analysis in an Admixed Population. 

o       1252. Determinants of HCV Antiviral Treatment in a Managed Care Setting. 

o       1253. Assessment of serum HCV RNA at week 12 post-treatment is as relevant as week 24 to predict SVR in patients with chronic hepatitis C treated with Pegylated interferon plus ribavirin.  (updated Nov 4, 2008)

o       1261. The Impact Of A Multi-Disciplinary Support Program On Adherence And The Efficacy Of Hepatitis C Treatment. (updated Nov 3, 2008)

o       1266. Education Program (Ep) Improves The Rate Of Sustained Virologic Response (Svr) To Anti-HCV Therapy: Multivariate Analysis From A French Network Experience. (updated Nov 3, 2008)

o       1271. Insulin Resistant Chronic Hepatitis C (CHC): The Effect of Sustained Virological Response (SVR) on Insulin Resistance (IR) Status, Insulin Secretion, Lipid Profile and Adiponectin.  

o       1290. A retrospective comparative study of Pegylated interferon and ribavirin for the treatment of chronic hepatitis C genotype 6 and genotype 1. (updated Nov 3, 2008)

o       1314. Long-term efficacy of peginterferon with ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related advanced fibrosis. 

o       1317. Differences in Adherence to PEG-Interferon and Ribavirin Among Subgroups Perceived to be At-Risk for Non-Adherence.  (updated Nov 4, 2008)  

o       1321. Effectiveness of Hepatitis C Treatment with Pegylated Interferon and Ribavirin in an Urban Patient Population. 

o       1325. Outcomes of Antiviral Therapy for Hepatitis C in Day to Day Clinical Practice.  (updated Nov 4, 2008)

o       1338. Management of Chronic Hepatitis C Patients with Schizophrenia: Should we treat? 

o       1945. Association of Lipid Profiles with Hepatitis C Viral Load in Chronic Hepatitis C Patients with Genotype 1 and 2 Infection. 

 

·        IDU

o       1257. Adherence and response rate to anti viral treatment do not seem to be affected by intravenous drug use in patients with chronic hepatitis C under substitution therapy.   (updated Nov 3, 2008)

o       1286. Specific joint hepatology–addiction medicine follow-up of hepatitis C treatment for intravenous drug users (IDU) or ex-IDU improves treatment response. (updated Nov 3, 2008)

o       1297. Impact of Recent Substance Use on Antiviral Treatment for Chronic Hepatitis C.   (updated Nov 3, 2008)

o       1305. Three year follow-up of a multidisciplinary care and peer support model for the engagement of IDUs in care and treatment for HCV infection. 

 

·        Infergen

o       1310. Efficacy Of Daily Dose Consensus Interferon Alfacon-1(CIFN) And Ribavirin In Previous Non Responders To Pegylated Interferon and Ribavirin In Patients With Advanced Fibrosis From Chronic Hepatitis C. (updated Nov 4, 2008)

 

·        Pegasys

o       LB6. Metformin with Peginterferon Alfa-2a and Ribavirin in the Treatment of Naïve Genotype 1 Chronic Hepatitis C Patients with Insulin Resistance (TRIC-1): Final Results of a Randomized and Double-Blinded Trial. 

o       265. Changes in Health-Related Quality of Life are Associated with Disease Progression and Peginterferon Therapy in Patients with Advanced Hepatitis C in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial.

o       271. Reduction of Insulin Resistance with Effective Clearance of Hepatitis C Infection: Results from the HALT-C Trial. 

o       273. Reduced Hepatic Inflammation is Related to HCV RNA Suppression and Correlates With Less Fibrosis Progression and Fewer Cirrhosis Complications in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.

o       512. Alfa-2a monotherapy could be a treatment option for Chronic Hepatitis C in Patients Infected with HCV Genotype 2. 

o       1227. High rates of sustained virological response in HCV-infected injection drug users receiving directly observed therapy with peginterferon alfa-2a and once daily ribavirin.  (updated Nov 3, 2008)

o       1239. Are there differences in treatment outcomes between HCV genotype 2 and 3 patients with advanced fibrosis treated with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®)? 

o       1243. Effect of Time to Response on Viral Breakthrough and Relapse Rates in Patients Infected With HCV Genotype 1 and Treated With Peginterferon Alfa-2a Plus Ribavirin. 

o       1251. Very Low Viral Load (VLVL) Relapse after Treatment for HCV: A unique group with High Sustained Virologic Response (SVR) to low dose, Short Course Retreatment. (updated Nov 3, 2008)  

o       1256. Higher Response Rate from Peginterferon Alpha 2a Plus Ribavirin in Chronic Hepatitis C Patients with Hemophilia.  

o       1295. Sustained Virologic Response Is Associated With Worse Qol During And Improved Qol After Treatment With Peginterferon Alfa-2a And Ribavirin.  (updated Nov 3, 2008)

o       1860. High sustained virologic response rates in HCV genotype 1 relapser patients retreated with peginterferon alfa-2a (40KD) plus ribavirin for 72 weeks.  

o       1862. Histologic Response to Peginterferon Alfa-2a Plus Ribavirin in Treatment-Naive Latino and Non-Latino White Patients Infected With HCV Genotype 1: The LATINO Study.  

o       1864. Pharmacokinetics (PK) of ribavirin (RBV) in patients with renal impairment or end-stage renal disease (ESRD) and chronic hepatitis C (CHC) during treatment with peginterferon alfa-2a (40KD) (PEGASYS®) and RBV (COPEGUS®).

o       1873. A 72-week treatment duration with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) has a favorable risk:benefit ratio in non-responders to pegylated interferon alfa-2b (12KD) plus ribavirin: findings of the multinational REPEAT study.  

 

·        PEG-Intron

o       1216. Impact of Advanced Fibrosis and Cirrhosis on Sustained Virologic Response of HCV G1-Infected Patients: Results of The Canadian POWeR Program. 

o       1222. Impact of the use of drugs and substitution treatments on the antiviral treatment of chronic hepatitis C (HCV): analysis of compliance, virological response and quality of life (Cheobs). 

o       1224. Extended treatment with peginterferon alfa-2b and ribavirin combination therapy can suppress the relapse rate after treatment of chronic hepatitis C genotype 1 patients with late viral response.  (updated Nov 3, 2008)

o       1229. Virological Response to Treatment with Pegylated Interferon alfa-2b and ribavirin chronic hepatitis C in Children.  (updated Nov 3, 2008)

o       1282. Effect of Interferon alfa-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. (updated Nov 3, 2008)

 

·        Predictors of Treatment Response

o       268. Sustained Virologic Response (SVR) and Predictors of Response in African American (AA) Patients in the IDEAL (Individualized Dosing Efficacy Versus Flat Dosing to Assess OptimaL Pegylated Interferon Therapy) Phase 3b Study. 

o       270. Es-Citalopram for the prevention of PEG-IFN-α and Ribavirin associated depression in HCV-infected patients without psychiatric risk factors (CIPPAD-study).

o       1019. Hepatitis C Viral Genotype Age is a Predictor of the Clinical Response to Interferon Therapy. 

o       1249. Effect of obesity on interferon stimulated genes expression in chronic HCV infection. 

o       1259. Steatosis, Insulin resistance, Iron overload, Fibrosis and Viral load as negative factors affecting Early (EVR) and Sustained (SVR) Virological Response in patients with Chronic Hepatitis C treated with peginterferon and ribavirin. 

o       1260. Monitoring virologic on treatment response to predict treatment outcome in patients with chronic hepatitis C treated with pegylated interferon plus ribavirin: realtime PCR assays and bDNA/TMA provide the same performances. (updated Nov 3, 2008)

o       1270. Insulin-Resistance in Chronic Hepatitis C patients: New Predictor of Sustained Virological Response Independent of HCV Genotype and Liver Fibrosis Stage. (updated Nov 3, 2008)

o       1273. Asian Ethnicity is a Significant Predictor of Sustained Virologic Response (SVR) to Combination Therapy with Peginterferon (PEG IFN) and Ribavirin (RBV) in Chronic Hepatitis C (CHC). 

o       1301. Relationship between insulin resistance (IR) and sustained virologic response (SVR) in the treatment of Hepatitis C virus (HCV) with interferon and ribavirin.  (updated Nov 4, 2008)

o       1334. Does steatosis influence the effect of therapy and the progression of chronic liver disease caused by HCV? 

o       1336. Insulin resistance, LDL cholesterol and results of hepatitis C treatment. 

 

·        RibaPak

o       1302. Treatment compliance in patients taking RibaPak® or 200mg ribavirin: Preliminary analyses from the ADHERE registry. 

 

·        Side Effects

o       1263. Prospective Analysis of Depression During Antiviral Treatment for Hepatitis C: Results of the VIRAHEP-C Study.  

o       1284. Central Hypothyroidism in patients with chronic hepatitis C. 

o       1300. Autoimmune Thyroid Disease In Chronic Hepatitis C Treated With Peg-IFN And Ribavirin: Prevalence, Incidence And Influence On Therapeutic Outcome In 4498 Naive Patients.  

o       1309. Importance of prior psychiatric consultation in pegylated interferon and ribavirin combination therapy for chronic hepatitis C. 

 

·        Side Effect Management

o       209. Do growth factors improve SVR in chronic HCV-genotype 1 patients treated with Peg-Interferon and Ribavirin?

 

·        Substitute Opioid Therapy

o       1311. Pegylated Interferon Alfa-2a (Peg-2a) Plus Ribavirin (RBV) For Patients With Chronic Hepatitis C Virus (HCV) On Opioid Pharmacotherapy: Virological Outcomes, Psychological Impact And Safety.

o       1335. Psychopathological Changes and Quality of Life in HCV-Infected, Opioid-Dependent Patients During Maintenance therapy.